Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 6/2005

01.12.2005 | Review Article

The Psychosocial Burden of Psoriasis

verfasst von: Dr Alexa B. Kimball, Christine Jacobson, Stefan Weiss, Mary G. Vreeland, Ying Wu

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Background: Skin diseases such as psoriasis can profoundly influence a patient’s self-image, self-esteem, and sense of well-being. Psoriasis is a multifactorial inflammatory condition with a disease burden that extends beyond the physical symptoms experienced by patients. Psoriasis affects all aspects of quality of life, including physical, psychologic, social, sexual, and occupational elements.
Objective: The goal of this article was to review the published literature on the impact of psoriasis on quality of life.
Methods: Relevant studies were identified through a comprehensive search of MEDLINE, EMBASE, and the Derwent Drug File databases of English-language articles published between 1993 and 2005 using the terms psoriasis in combination with quality of life, cost, cost-benefit analysis, economic, employment, days lost, healthcare, hospitalization, managed care, outcomes research, occupation, payers, and psychosocial. The reference lists of identified articles were checked for additional studies that might have been missed in the original searches.
Results: Data suggest that social stigmatization, high stress levels, physical limitations, depression, employment problems and other psychosocial co-morbidities experienced by patients with psoriasis are not always proportional to, or predicted by, other measurements of disease severity such as body surface area involvement or plaque severity.
Conclusion: It is essential to include measures of psychosocial morbidity when assessing psoriasis severity and treatment efficacy because of the substantial role that psychosocial burden plays in patient perception of disease severity, quality of life, and disease course.
Literatur
1.
2.
Elder IT, Nair RP, Henseler T, et al. The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol. 2001; 137 (11): 1447–54PubMed
3.
Ameen M. Genetic basis of psoriasis vulgaris and its pharmacogenetic potential. Pharmacogenomics. 2003; 4 (3): 297–308PubMedCrossRef
4.
Prinz JC. The role of T cells in psoriasis. J Fur Acad Dermatol Venereol. 2003; 17 (3): 257–70CrossRef
5.
Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002; 46 (6): 850–60PubMedCrossRef
6.
Stern RS. Inpatient hospital care for psoriasis: a vanishing practice in the United States. J Am Acad Dermatol. 2003; 49 (3): 445–50PubMedCrossRef
7.
8.
9.
Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985; 13 (3): 450–6PubMedCrossRef
10.
Ferrandiz C, Pujol RM, Garcia-Patos V, et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002; 46 (6): 867–73PubMedCrossRef
11.
Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002; 47 (4): 512–8PubMedCrossRef
12.
Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001; 137 (3): 280–4PubMed
13.
Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995; 32 (6): 982–6PubMedCrossRef
14.
Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol. 2003; 48 (6): 805–21PubMedCrossRef
15.
Wahl A, Loge JH, Wiklund I, et al. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol. 2000; 43 (5 Pt 1): 803–8PubMedCrossRef
16.
Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. J Am Acad Dermatol. 2000; 43 (2 Pt 1): 281–5PubMedCrossRef
17.
Perrott SB, Murray AH, Lowe J, et al. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav. 2000; 70 (5): 567–71PubMedCrossRef
18.
Richards HL, Fortune DG, Griffiths CE, et al. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res. 2001; 50 (1): 11–5PubMedCrossRef
19.
Zachariae R, Zachariae H, Blomqvist K, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol. 2002; 146 (6): 1006–16PubMedCrossRef
20.
Touw CR, Hakkaart-Van Roijen L, Verboom P, et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol. 2001; 144 (5): 967–72PubMedCrossRef
21.
Chren MM. Understanding research about quality of life and other health outcomes. J Cutan Med Surg. 1999; 3 (6): 312–6PubMed
22.
Gupta G, Long J, Tillman DM. The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures. Br J Dermalot. 1999; 140 (5): 887–90CrossRef
23.
Wahl A, Mourn T, Hanestad BR, et al. The relationship between demographic and clinical variables, and quality of life aspects in patients with psoriasis. Qual Life Res. 1999; 8 (4): 319–26PubMedCrossRef
24.
Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41 (3 Pt 1): 401–7PubMedCrossRef
25.
Kirby B, Fortune DG, Bhushan M, et al. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol. 2000; 142 (4): 728–32PubMedCrossRef
26.
Snaith RP. The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes. 2003; 1 (1): 29PubMedCrossRef
27.
Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996; 14 (3): 485–96PubMedCrossRef
28.
Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49 (2 Suppl.): S57–61PubMedCrossRef
29.
Koo J, Kozma CM, Reinke K. The development of a disease-specific questionnaire to assess the quality of life for psoriasis patients: an analysis of the reliability, validity, and responsiveness of the psoriasis quality of life questionnaire. Dermatol Psychosom. 2002; 3: 171–9CrossRef
30.
Koo J, Kozma CM, Menter A, Lebwohl M. Development of the 12 item psoriasis quality of life questionnaire (PQOL) [poster no. 606]. 61 st Annual Meeting of the American Academy of Dermatology; 2003 Mar 21–26; San Francisco (CA)
31.
Jenner N, Campbell J, Plunkett A, et al. Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol. 2002; 43 (4): 255–61PubMedCrossRef
32.
McHenry PM, Doherty VR. Psoriasis: an audit of patients’ views on the disease and its treatment. Br J Dermatol. 1992; 127 (1): 13–7PubMedCrossRef
33.
Root S, Kent G, al-Abadie MS. The relationship between disease severity, disability and psychological distress in patients undergoing PUVA treatment for psoriasis. Dermatology. 1994; 189 (3): 234–7PubMedCrossRef
34.
Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000; 143 (5): 969–73PubMedCrossRef
35.
Fortune DG, Richards HL, Main CJ, et al. What patients with psoriasis believe about their condition. J Am Acad Dermatol. 1998; 39 (2 Pt 1): 196–201PubMedCrossRef
36.
Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological and social impact of psoriasis. J Health Psychol. 1997; 2: 525–37PubMedCrossRef
37.
Rapp SR, Feldman SR, Fleischer AB, et al. Health-related quality of life in psoriasis: a biopsychosocial model and measures. In: Rajagopalan R, Sherertz E, Anderson R, editors. Care and management of skin diseases: life quality and economic impact. New York: Marcel Dekker,; 1998: 125–45
38.
Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol. 1995; 75 (3): 240–3PubMed
39.
Gupta MA, Gupta AK, Schork NJ, et al. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med. 1994; 56 (1): 36–40PubMed
40.
Wahl AK, Gjengedal E, Hanestad BR. The bodily suffering of living with severe psoriasis: in-depth interviews with 22 hospitalized patients with psoriasis. Qual Health Res. 2002; 12 (2): 250–61PubMedCrossRef
41.
Pettey AA, Balkrishnan R, Rapp SR, et al. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003; 49 (2): 271–5PubMedCrossRef
42.
Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995; 132 (2): 236–44PubMedCrossRef
43.
Finlay AY, Kelly SE. Psoriasis: an index of disability. Clin Exp Dermatol. 1987; 12 (1): 8–11PubMedCrossRef
44.
Finlay AY, Khan GK, Luscombe DK, et al. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol. 1990; 123 (6): 751–6PubMedCrossRef
45.
de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology. 1996; 193 (4): 300–3PubMedCrossRef
46.
Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Associations: data from the Nordic Quality of Life Study. Acta Derm Venereol. 2002; 82 (2): 108–13PubMedCrossRef
47.
Lundberg L, Johannesson M, Silverdahl M, et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000; 80 (6): 430–4PubMedCrossRef
48.
Gladman DD, Rahman P. Psoriatic arthritis. In: Ruddy S, Harris ED, Sledge CB, et al., editors. Kelley’s textbook of rheumatology. 6th ed. Philadelphia (PA): WB Saunders Company,. 2001: 1071–8
49.
Baughman RD, Sobel R. Psoriasis: a measure of severity. Arch Dermatol; 1970; 101 (4): 390–5PubMedCrossRef
50.
Schmid-Ott G, Jaeger B, Kuensebeck HW, et al. Dimensions of stigmatization in patients with psoriasis in a ‘Questionnaire on Experience with Skin Complaints’. Dermatology; 1996; 193 (4): 304–10PubMedCrossRef
51.
Ginsburg IH, Link BG. Psychosocial consequences of rejection and stigma feelings in psoriasis patients. Int J Dermatol. 1993; 32 (8): 587–91PubMedCrossRef
52.
Fried RG, Friedman S, Paradis C, et al. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol. 1995; 34 (2): 101–5PubMedCrossRef
53.
Gupta MA, Gupta AK, Watteel GN. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis. 1998; 61 (6): 339–42PubMed
54.
Vardy D, Besser A, Amir M, et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol. 2002; 147 (4): 736–42PubMedCrossRef
55.
Gupta MA, Gupta AK. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol. 1995; 34 (10): 700–3PubMedCrossRef
56.
Akay A, Pekcanlar A, Bozdag KE, et al. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Fur Acad Dermatol Venereol. 2002; 16 (4): 347–52CrossRef
57.
Fortune DG, Main CJ, O’Sullivan TM, et al. Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. J Psychosom Res. 1997; 42 (5): 467–75PubMedCrossRef
58.
Devrimci-Ozguven H, Kundakci TN, Kumbasar H, et al. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Fur Acad Dermatol Venereol. 2000; 14 (4): 267–71CrossRef
59.
Nyfors A, Lemholt K. Psoriasis in children: a short review and a survey of 245 cases. Br J Dermatol. 1975; 92 (4): 437–42PubMedCrossRef
60.
Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol. 1997; 36 (4): 259–62PubMedCrossRef
61.
Ramsay B, O’Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol. 1988; 118 (2): 195–201PubMedCrossRef
62.
de Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001; 144 Suppl. 58: 33–6
63.
Feldman SR, Fleischer Jr AB, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997; 37 (4): 564–9PubMedCrossRef
64.
Fortune DG, Main CJ, O’Sullivan TM, et al. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol. 1997; 137 (5): 755–60PubMedCrossRef
65.
Fleischer Jr AB, Feldman SR, Bradham DD. Office-based physician services provided by dermatologists in the United States in 1990. J Invest Dermatol. 1994; 102 (1): 93–7PubMedCrossRef
66.
Gelfand JM, Berlin J, Van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol. 2003; 139 (11): 1425–9PubMedCrossRef
67.
Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998; 139 (5): 846–50PubMedCrossRef
68.
Hardy GE, Cotterill JA. A study of depression and obsessionality in dysmorphophobic and psoriatic patients. Br J Psychiatry. 1982; 140: 19–22PubMedCrossRef
69.
Scharloo M, Kaptein AA, Weinman J, et al. Patients’ illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol. 2000; 142 (5): 899–907PubMedCrossRef
70.
Farber EM, Nall L. Psoriasis and alcoholism. Cutis. 1994; 53 (1): 21–7PubMed
71.
Wolf R, Wolf D, Ruocco V. Alcohol intake and psoriasis. Clin Dermatol. 1999; 17 (4): 423–30PubMedCrossRef
72.
Higgins EM, du Vivier AW. Alcohol abuse and treatment resistance in skin disease [letter]. J Am Acad Dermatol. 1994; 30 (6): 1048PubMedCrossRef
73.
Higgins EM, du Vivier AW. Cutaneous disease and alcohol misuse. Br Med Bull. 1994; 50 (1): 85–98PubMed
74.
Higgins EM, du Vivier AW. Alcohol and the skin. Alcohol Alcohol. 1992; 27 (6): 595–602PubMed
75.
Gupta MA, Schork NJ, Gupta AK, et al. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol. 1993; 28 (5 Pt 1): 730–2PubMedCrossRef
76.
Vincenti GE, Blunden SM. Psoriasis and alcohol abuse. J R Army Med Corps. 1987; 133 (2): 77–8PubMed
77.
Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol. 1999; 135 (12): 1490–3PubMedCrossRef
78.
Gottlieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov. 2005; 4 (1): 19–34PubMedCrossRef
79.
Lebwohl M, Ting PT, Koo JY. Psoriasis treatment: traditional therapy. Ann Rheum Dis. 2005; 64 Suppl. 2: ii83–6CrossRef
80.
Salek MS, Finlay AY, Lewis JJ, et al. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral). Qual Life Res. 2004; 13 (1): 91–5PubMedCrossRef
81.
Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003; 4 (2): 131–9PubMedCrossRef
82.
Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. 2004; 150 (2): 317–26PubMedCrossRef
83.
Ricardo RR, Rhoa M, Orenberg EK, et al. Clinical benefits in patients with psoriasis after efalizumab therapy: clinical trials versus practice. Cutis. 2004; 74 (3): 193–200PubMed
84.
Nijsten T, Margolis DJ, Feldman SR, et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol. 2005; 52 (3 Pt 1): 434–44PubMedCrossRef
85.
Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004; 51 (2): 212–6PubMedCrossRef
86.
Richards HL, Fortune DG, O’Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999; 41 (4): 581–3PubMed
87.
Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004; 140 (4): 408–14PubMedCrossRef
88.
Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004; 151 (4): 895–7PubMedCrossRef
89.
Fortune DG, Richards HL, Kirby B, et al. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002; 146 (3): 458–65PubMedCrossRef
90.
Richards HL, Fortune DG, Weidmann A, et al. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol. 2004; 151 (6): 1227–33PubMedCrossRef
91.
Seng TK, Nee TS. Group therapy: a useful and supportive treatment for psoriasis patients. Int J Dermatol. 1997; 36 (2): 110–2PubMedCrossRef
92.
Zachariae R, Oster H, Bjerring P, et al. Effects of psychologic intervention on psoriasis: a preliminary report. J Am Acad Dermatol. 1996; 34 (6): 1008–15PubMedCrossRef
Metadaten
Titel
The Psychosocial Burden of Psoriasis
verfasst von
Dr Alexa B. Kimball
Christine Jacobson
Stefan Weiss
Mary G. Vreeland
Ying Wu
Publikationsdatum
01.12.2005
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 6/2005
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200506060-00005

Weitere Artikel der Ausgabe 6/2005

American Journal of Clinical Dermatology 6/2005 Zur Ausgabe

Current Opinion

Oral Contraceptives and Skin Cancer

Leading Article

Monitoring Liver Function during Methotrexate Therapy for Psoriasis

Review Article

Human Papillomavirus

Review Article

The Role of Hyaluronic Acid in Wound Healing

Case Reports

Monilethrix

BookReview

Book Reviews

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise